Premium
Voriconazole inhibition of vitamin A metabolism: Are adverse events increased in cystic fibrosis patients?
Author(s) -
Cheng Matthew Pellan,
Paquette Katryn,
Lands Larry C.,
Ovetchkine Philippe,
Théoret Yves,
Quach Caroline
Publication year - 2010
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.21234
Subject(s) - medicine , cystic fibrosis , voriconazole , adverse effect , metabolism , gastroenterology , physiology , intensive care medicine , dermatology , antifungal
Background As Voriconazole is being used more frequently in cystic fibrosis (CF) patients, we aimed to describe the adverse events associated with voriconazole treatment in this population. Methods We performed a retrospective cohort study of all children with CF who received voriconazole between September 2006 and August 2008. Results Five of six CF patients receiving treatment developed photosensitivity, whereas all six patients reported visual disturbances. We report two clinical cases of particular interest: a 7‐year‐old boy developed striking erythema in the face and upper thorax; a 16‐year‐old girl who reported unexpected visual disturbances, including scotomas and tunneling vision. Conclusion Significant adverse effects of voriconazole were noted in all treated CF patients. We speculate that this may be due to suppression of activity of hepatic enzymes involved in all transretinonic acid metabolism coupled with vitamin A supplementation in CF. Consideration should be given to reducing vitamin A supplementation during voriconazole treatment. Pediatr Pulmonol. 2010; 45:661–666. © 2010 Wiley‐Liss, Inc.